Loomis Sayles & CO L P Incyte Corp Transaction History

Loomis Sayles & CO L P

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$52.16 - $64.19 $1,773 - $2,182	-34 Reduced 28.81%	84 $5,000
Q3 2023 Nov 09, 2023	BUY	$57.77 - $65.93 $4,159 - $4,746	72 Added 156.52%	118 $7,000
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $2,803 - $3,473	46 New	46 $3,000
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $9,993 - $12,511	-151 Reduced 6.97%	2,015 $134,000
Q2 2022 Aug 05, 2022	SELL	$66.18 - $83.18 $2,713 - $3,410	-41 Reduced 1.86%	2,166 $165,000
Q1 2022 May 13, 2022	SELL	$66.02 - $79.71 $172,906 - $208,760	-2,619 Reduced 54.27%	2,207 $175,000
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $305,678 - $357,654	4,826 New	4,826 $354,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

Stay updated on Loomis Sayles & CO L P with notifications on news.